Dr. Milos Petrovic

Dr. Milos Petrovic

Reader in Neuroscience

School of Pharmacy and Biomedical Sciences

Maudland Building, MB140

+44 (0) 1772 89 5846

Dr Petrovic has gained teaching and research experience while working in Serbia, Czech Republic, UK and Spain. His current research interests include synaptic physiology and pathophysiology with an emphasis on electrophysiological, imaging and molecular biology techniques.

Within the Neuroscience theme, Dr Petrovic is a member of Neurodegeneration and Molecular Psychiatry research groups.

Full Profile

Dr Petrovic graduated from School of Medicine, University of Belgrade, Serbia, where he continued his initial academic training (MSc under the supervision of Prof. Dusan Mitrovic) and career (teaching assistant, Institute of Medical Physiology). He completed his PhD in neuroscience at the Institute of Physiology, Academy of Sciences, Prague, Czech Republic, under the supervision of Dr Ladislav Vyklicky. His thesis was focused on the effect of neurosteroids on the activity of NMDA receptors.

Dr Petrovic continued his training by post-docs in Czech Republic (IBRO Research Fellowship), UK (University of Bristol, Marie Curie Fellowship) and Spain (University of Navarra, Marie Curie Integration Grant).

Throughout that period, his work was primarily based on patch-clamp electrophysiology in cultured cells, as well as brain slices (e.g. hippocampal and striatal).

Recently, Dr Petrovic was awarded an MRC New Investigator Grant, thus initiating the work on forming his research lab at UCLan.

Currently active projects are:

  • The role of dopamine receptors in L-DOPA-induced dyskinesia
  • The role of kainate receptors in synaptic plasticity



  • Medical doctor, 1998, School of Medicine, University of Belgrade, Serbia
  • Clinical specialist, Internal medicine, 2007, School of Medicine, University of Belgrade, Serbia


  • MSc, Human Physiology and Pathophysiology, 2002, School of Medicine, University of Belgrade, Serbia
  • PhD, Neuroscience, 2005, 1st School of Medicine, Charles University, Prague, Czech Republic


  • British Neuroscience Association
  • Fellow of Higher Education Academy


Research Degree Tutor for the School of Pharmacy and Biomedical Sciences


  • BSc Biomedical Science
  • BSc Physiology and Pharmacology
  • MPharm Pharmacy


  • PJ1301 : Health and Disease
  • PJ2200 : Systems Pharmacology 2
  • BL2224 : Contemporary Cell Biology Techniques
  • BL3220 : Advanced Systems Pharmacology
  • BL3298 : Group Research Project (Module Tutor)
  • BL3299 : Research Project (Module Tutor)
  • PJ3997 : Research Methods & Project Dev


Petrovic MM, Viana da Silva S, Clement JP, Vyklicky L, Mulle C, González-González IM, Henley JM. (2017) “Metabotropic action of postsynaptic kainate receptors triggers hippocampal long-term potentiation”, Nat Neurosci. 2017 Apr;20(4):529-539. doi: 10.1038/nn.4505. Epub 2017 Feb 13.

Marco S, Giralt A, Petrovic MM, Pouladi MA, Martínez-Turrillas R, Martínez-Hernández J, Kaltenbach LS, Torres-Peraza J, Graham RK, Watanabe M, Luján R, Nakanishi N, Lipton SA, Lo DC, Hayden MR, Alberch J, Wesseling JF, Pérez-Otaño I. (2013). “Reversing aberrant GluN3A expression rescues synapse loss and motor and cognitive dysfunction in HD mouse models”, Nature Medicine, 2013 Jul 14. doi: 10.1038/nm.3246.

Petrovic MM, Nowacki J, Olivo V, Tsaneva-Atanasova K, Randall A, Mellor J. (2012). “Inhibition of post-synaptic Kv7/KCNQ/M channels facilitates Long-Term Potentiation in the Hippocampus”. PLoS ONE 7(2): e30402. doi:10.1371/journal.pone.0030402.

Craig TJ, Jaafari N, Petrovic MM, Rubin PP, Mellor JR, Henley JM (2012). “Homeostatic synaptic scaling is regulated by protein SUMOylation”, JBC, 287(27):22781-8.

Buchanan KA*, Petrovic MM*, Chamberlain SEL, Marrion NV, Mellor JR. (2010). “Facilitation of Long-Term Potentiation by Muscarinic M1 Receptors in the Hippocampus is mediated by inhibition of SK channels”. Neuron 68(5):948-963, *equal contribution

Petrovic M, Sedlacek M, Horak M, Chodounska H, Ladislav Vyklicky Jr. (2005). “20-oxo-5β-pregnan-3α-yl sulfate is a use-dependent NMDA receptor inhibitor”. J. Neurosci. 25(37):8439–8450.